0JQ2.LKALA BIO, Inc.

Über

Kala Bio, Inc. operates as a biopharmaceutical enterprise focused on developing and bringing to market innovative treatments. The company employs its unique, proprietary nanoparticle technology, designed to effectively penetrate mucus barriers. Initially, its efforts are concentrated on addressing various ocular conditions. Established in 2009 by founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, the firm maintains its headquarters in Arlington, Massachusetts.

www.kalarx.com

Kennzahlen

Marktkapitalisierung

254.16K

EPS

-165.50

Dividendenrendite

0.00%

Beta

-2.41

KBV

0.64

EK-Rendite

-385.6%

Sektor

Healthcare

Branche

Biotechnology

CEO

Avi Minkowitz

Mitarbeiter

38

IPO-Datum

2018-01-29

Land

US